An Educational Intervention to Improve Statin Use: Cluster RCT at the Primary Care Level in Argentina

Statins are essential drugs for high cardiovascular disease (CVD) risk management; however, there is still low adherence to good clinical practice guidelines for statin use at the primary care level in low- and middle-income countries. This study aimed to test whether a complex intervention targetin...

Full description

Saved in:
Bibliographic Details
Published in:American journal of preventive medicine 2019-07, Vol.57 (1), p.95-105
Main Authors: Gulayin, Pablo E., Lozada, Alfredo, Beratarrechea, Andrea, Gutierrez, Laura, Poggio, Rosana, Chaparro, Raúl Martín, Santero, Marilina, Masson, Walter, Rubinstein, Adolfo, Irazola, Vilma
Format: Article
Language:English
Subjects:
Cardiovascular diseases
Cholesterol
Clinical medicine
Clinical practice guidelines
Control groups
Density
Educational programs
Evidence-based medicine
Health promotion
Hypercholesterolemia
Intervention
Physicians
Primary care
Risk management
Risk reduction
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statins are essential drugs for high cardiovascular disease (CVD) risk management; however, there is still low adherence to good clinical practice guidelines for statin use at the primary care level in low- and middle-income countries. This study aimed to test whether a complex intervention targeting physicians improves treatment and control of hypercholesterolemia among patients with moderate to high CVD risk in Argentina. Cluster RCT. Ten primary care centers from the public healthcare system of Argentina. Primary care physicians in the intervention group received an educational program with three main components: (1) an intensive 2-day training workshop; (2) educational outreach visits; and (3) a mobile health application installed on the physician's smartphones. Reduction in mean low-density lipoprotein cholesterol level, reduction in mean Framingham risk score, proportion of patients receiving an appropriate statin dose, and mean annual number of primary care center visits. Data were analyzed in 2017–2018. Between April 2015 and April 2016, a total of 357 participants were enrolled (179 patients in the intervention group and 178 in the control group). The global follow-up rate was 97.2%. At the end of the follow-up period, there was no difference in low-density lipoprotein cholesterol levels in any of the follow-up points among the groups. Mean CVD risk had a significant net difference in the first 6 months in the intervention group versus the control group (–4.0, 95% CI = –6.5, –1.5). At the end of follow-up, there was an absolute 41.5% higher rate of participants receiving an appropriate statin dose in the intervention group versus the control group. Although the intervention did not reach a reduction in cholesterol levels, it had a significant positive impact on the promotion of adequate use of clinical practice guidelines. This study is registered at www.clinicaltrials.gov NCT02380911.
ISSN:0749-3797
1873-2607
DOI:10.1016/j.amepre.2019.02.018